Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Huić, M. (2021): Bamlanivimab monotherapy and as combination therapy (with Etesevimab) for Covid-19. AIHTA Policy Brief 009.

Huić, M. and Swiss Network for HTA, (SNHTA) (2021): Combination therapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of Covid-19. AIHTA Policy Brief 008.

Wild, C and Wolf, S and Goetz, G and Walter, M and McEntee, J and Stanak, M and Ettinger, S and Strohmaier, C and Erdos, J and Huić, M (2020): Covid-19: HSS/ Horizon Scanning Living Document. AIHTA Policy Brief 002.

Wild, C. (2003): [High-dose lymphoablative therapy (HDLT) for severe autoimmune diseases]. HTA-Newsletter 21: pp. 2-3.